JPH2
Basic information
Region (hg38): 20:44106590-44187188
Links
Phenotypes
GenCC
Source:
- hypertrophic cardiomyopathy 17 (Moderate), mode of inheritance: AD
- hypertrophic cardiomyopathy 17 (Strong), mode of inheritance: AD
- cardiomyopathy, dilated, 2E (Limited), mode of inheritance: Unknown
- dilated cardiomyopathy (Moderate), mode of inheritance: Semidominant
- hypertrophic cardiomyopathy (Moderate), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Cardiomyopathy, familial hypertrophic 17; Cardiomyopathy, dilated, 2E | AD/AR | Cardiovascular | In both hypertrophic and dilated forms of cardiomyopathy, surveillance and medical management, may reduce morbidity; Cardiac transplant has been described in Dilated cardiomyopathy | Cardiovascular | 17476457; 17509612; 22515980; 30384889; 31227780 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the JPH2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 234 | 243 | ||||
missense | 440 | 452 | ||||
nonsense | 7 | |||||
start loss | 0 | |||||
frameshift | 10 | 10 | ||||
inframe indel | 16 | 16 | ||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 7 | 5 | 2 | 14 | ||
non coding | 50 | 27 | 79 | |||
Total | 0 | 1 | 479 | 293 | 35 |
Variants in JPH2
This is a list of pathogenic ClinVar variants found in the JPH2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
20-44113260-C-T | Benign (Nov 12, 2019) | |||
20-44113503-T-A | Cardiomyopathy, dilated, 2E;Hypertrophic cardiomyopathy 17 | Uncertain significance (Aug 20, 2021) | ||
20-44113618-T-G | Benign (Jun 25, 2020) | |||
20-44114513-G-A | Benign (Jun 19, 2018) | |||
20-44114523-G-A | Likely benign (Jun 19, 2018) | |||
20-44114565-AGT-A | Benign (Aug 18, 2019) | |||
20-44114565-AGTGT-A | Benign (Aug 15, 2019) | |||
20-44114565-AGTGTGT-A | Benign (Aug 15, 2019) | |||
20-44114565-AGTGTGTGT-A | Benign (Aug 06, 2019) | |||
20-44114565-AGTGTGTGTGTGTGTGTGT-A | Benign (Aug 10, 2019) | |||
20-44114565-A-AGT | Benign (Aug 15, 2019) | |||
20-44114607-T-C | Likely benign (Aug 13, 2019) | |||
20-44114609-T-C | Benign (Aug 08, 2019) | |||
20-44114609-T-TGC | Likely benign (Aug 20, 2019) | |||
20-44114609-T-TGCGC | Likely benign (Aug 21, 2019) | |||
20-44114658-G-A | Likely benign (Jun 18, 2018) | |||
20-44114767-G-A | not specified | Likely benign (Dec 20, 2016) | ||
20-44114793-C-T | Likely benign (Sep 07, 2018) | |||
20-44114802-C-A | Hypertrophic cardiomyopathy | Likely benign (Jan 07, 2023) | ||
20-44114802-CAG-C | Cardiovascular phenotype | Uncertain significance (Oct 22, 2020) | ||
20-44114809-T-A | Cardiovascular phenotype | Uncertain significance (Aug 27, 2022) | ||
20-44114810-G-C | Hypertrophic cardiomyopathy | Uncertain significance (Mar 15, 2023) | ||
20-44114813-C-T | Cardiovascular phenotype | Uncertain significance (Dec 14, 2022) | ||
20-44114813-CA-TG | Cardiovascular phenotype • Hypertrophic cardiomyopathy • Cardiomyopathy, dilated, 2E | Uncertain significance (Aug 13, 2024) | ||
20-44114814-A-G | not specified • Cardiovascular phenotype • Hypertrophic cardiomyopathy • Hypertrophic cardiomyopathy 17 | Benign (Feb 01, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
JPH2 | protein_coding | protein_coding | ENST00000372980 | 5 | 75884 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0000452 | 0.992 | 125724 | 0 | 23 | 125747 | 0.0000915 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.94 | 328 | 443 | 0.740 | 0.0000333 | 4311 |
Missense in Polyphen | 124 | 201.92 | 0.61412 | 1892 | ||
Synonymous | 2.20 | 172 | 213 | 0.808 | 0.0000181 | 1496 |
Loss of Function | 2.36 | 11 | 23.3 | 0.472 | 0.00000116 | 259 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000290 | 0.0000290 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.000625 | 0.000601 |
European (Non-Finnish) | 0.0000667 | 0.0000615 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000654 | 0.0000653 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Junctophilins contribute to the formation of junctional membrane complexes (JMCs) which link the plasma membrane with the endoplasmic or sarcoplasmic reticulum in excitable cells. Provides a structural foundation for functional cross-talk between the cell surface and intracellular calcium release channels. JPH2 is necessary for proper intracellular Ca(2+) signaling in cardiac myocytes via its involvement in ryanodine receptor-mediated calcium ion release. Contributes to the construction of skeletal muscle triad junctions. {ECO:0000269|PubMed:20095964}.;
- Disease
- DISEASE: Cardiomyopathy, familial hypertrophic 17 (CMH17) [MIM:613873]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:17509612, ECO:0000269|PubMed:24001019}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.144
Haploinsufficiency Scores
- pHI
- 0.164
- hipred
- Y
- hipred_score
- 0.594
- ghis
- 0.596
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.821
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Jph2
- Phenotype
- cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); muscle phenotype;
Gene ontology
- Biological process
- release of sequestered calcium ion into cytosol;regulation of cardiac muscle tissue development;calcium ion homeostasis;regulation of ryanodine-sensitive calcium-release channel activity;positive regulation of ryanodine-sensitive calcium-release channel activity;calcium ion transport into cytosol
- Cellular component
- endoplasmic reticulum;endoplasmic reticulum membrane;plasma membrane;junctional sarcoplasmic reticulum membrane;integral component of membrane;sarcoplasmic reticulum;Z disc;junctional membrane complex
- Molecular function
- phosphatidylserine binding;protein binding;phosphatidylinositol-4,5-bisphosphate binding;phosphatidylinositol-3,4,5-trisphosphate binding;phosphatidylinositol-5-phosphate binding;calcium-release channel activity;phosphatidylinositol-3-phosphate binding;phosphatidylinositol-4-phosphate binding;phosphatidic acid binding;phosphatidylinositol-3,5-bisphosphate binding